HCA Healthcare's Insiders' Timely Sale May Have Helped Mitigate 12% Dip in Share Price
HCA Healthcare's Insiders' Timely Sale May Have Helped Mitigate 12% Dip in Share Price
By selling US$15m worth of HCA Healthcare, Inc. (NYSE:HCA) stock at an average sell price of US$320 over the last year, insiders seemed to have made the most of their holdings. The company's market cap plunged by US$13b after price dropped by 12% last week but insiders were able to limit their loss to an extent.
通過在過去一年內以平均賣出價格爲每股320美元出售價值1500萬美元的hca醫療(紐交所:HCA)股票,內部人士似乎已充分利用了他們的持股。該公司市值在上週股價下跌12%後暴跌了130億美元,但內部人士能夠在一定程度上限制損失。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.
雖然我們永遠不會建議投資者僅基於公司董事已經做出的決策而做出決策,但同時我們認爲完全忽略內部交易是愚蠢的。
The Last 12 Months Of Insider Transactions At HCA Healthcare
hca醫療內部人士的最近12個月交易情況
Over the last year, we can see that the biggest insider sale was by the insider, Michael Cuffe, for US$2.0m worth of shares, at about US$317 per share. So it's clear an insider wanted to take some cash off the table, even below the current price of US$361. As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. Please do note, however, that sellers may have a variety of reasons for selling, so we don't know for sure what they think of the stock price. It is worth noting that this sale was only 18% of Michael Cuffe's holding.
在過去一年中,我們發現最大的內部人士賣出是由內部人士邁克爾·卡菲進行,價值200萬美元的股票,每股價格約爲317美元。因此,很明顯,一位內部人士希望獲得一些現金回報,即使低於當前361美元的股價。通常情況下,當內部人士以低於當前價格出售時,我們認爲這是令人沮喪的,因爲這表明他們對較低估值感到滿意。但請注意,賣方可能有各種出售理由,因此我們不能確定他們對股價的看法。值得注意的是,這筆交易僅佔邁克爾·卡菲持股的18%。
Insiders in HCA Healthcare didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
hca醫療內部人士在過去一年沒有購買任何股票。您可以看到過去12個月內部人士的交易情況(按公司和個人分類)的可視化描述。如果您想了解到底是誰以及以何價格何時出售的情況,請簡單點擊下方的圖表!
If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.
如果您和我一樣,您就不會錯過這個免費的小盤股票列表,這些股票不僅被內部人士購買,而且估值也很有吸引力。
Insider Ownership Of HCA Healthcare
hca醫療的內部所有權
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. It's great to see that HCA Healthcare insiders own 1.4% of the company, worth about US$1.3b. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
我喜歡看內部人擁有公司的股份數量,以幫助了解他們與內部人的一致性。如果內部人擁有公司股份的比例較大,我認爲這是一個好跡象。很高興看到hca醫療內部人擁有公司1.4%的股份,價值約13億美元。一般來說,內部人持有的如此大比例股份通常會增加公司爲了所有股東利益而運行的機會。
So What Does This Data Suggest About HCA Healthcare Insiders?
那麼,這些數據對hca醫療內幕人員有何暗示?
It doesn't really mean much that no insider has traded HCA Healthcare shares in the last quarter. While we feel good about high insider ownership of HCA Healthcare, we can't say the same about the selling of shares. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For example - HCA Healthcare has 1 warning sign we think you should be aware of.
在上個季度沒有內部人交易hca醫療股票並不意味着太多。雖然我們對hca醫療高內部所有權感到滿意,但我們無法對拋售股份表示同樣滿意。因此,了解內部人在買入或賣出方面的操作是有幫助的,同時也了解一家特定公司面臨的風險也是有幫助的。例如- hca醫療有1個我們認爲您應該注意的警告信號。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
當然,您可能會在其他地方找到一項出色的投資。因此,請查看此免費的有趣公司列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
譯文內容由第三人軟體翻譯。